PUMA BIOTECHNOLOGY INC (PBYI) Stock News
NASDAQ:PBYI - Nasdaq - US74587V1070 - Common Stock - Currency: USD
PBYI Latest News, Press Relases and Analysis
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock
Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of 400% and 4.65%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: KMDA
Puma Biotechnology Reports First Quarter Financial Results
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -105.56% and 13.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: APLS
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know
Puma Biotech (PBYI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Puma Biotechnology Reports Third Quarter 2024 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Second Quarter Financial Results
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
